Dermatological Drugs - Sweden

Sweden

The Dermatological Drugs market in Sweden is expected to experience significant growth in the coming years.
It is projected that by 2024, the revenue in this market will reach US$102.90m.
This growth is anticipated to continue at an annual growth rate of 5.71% from 2024 to 2028, resulting in a market volume of US$128.50m by the end of 2028.
When compared globally, it is worth noting that United States will generate the highest revenue in the Dermatological Drugs market.
In 2024, the revenue United States is estimated to be US$13,260.00m, indicating its dominance in this market.
In Sweden, the demand for dermatological drugs is driven by a strong focus on skincare and a high awareness of the importance of maintaining healthy skin.

Key regions: Brazil, Germany, Italy, Australia, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for dermatological drugs in Sweden has been on the rise in recent years.

Customer preferences: Swedish consumers are increasingly becoming more conscious about their skin health and are willing to invest in products that can help them achieve a better complexion. The popularity of organic and natural ingredients in skincare products has also influenced the demand for dermatological drugs.

Trends in the market: One of the major trends in the Swedish dermatological drugs market is the increasing demand for prescription drugs. The prevalence of skin diseases such as eczema and psoriasis has led to a growing need for prescription drugs that can effectively treat these conditions. Another trend is the rise in demand for anti-aging products, which has been driven by the aging population in Sweden.

Local special circumstances: Sweden's cold and dry climate can be harsh on the skin, which has led to a high demand for moisturizing products. The country's strict regulations on cosmetic products have also influenced the market, as consumers are more likely to trust products that have been approved by the Swedish Medical Products Agency.

Underlying macroeconomic factors: Sweden's strong economy and high disposable income levels have contributed to the growth of the dermatological drugs market. The country's healthcare system also plays a role, as prescription drugs are subsidized by the government, making them more affordable for consumers. Additionally, the increasing popularity of e-commerce has made it easier for consumers to access a wider range of dermatological drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.